Cara Therapeutics (NASDAQ:CARA) stock is falling hard on Thursday after the development-stage biopharmaceutical company announced new data from a clinical trial.This data comes from the company’s Part A KOURAGE-1 study. It’s designed to determine the dose that will be used for the drug during later parts of the clinical trial. The bad news here is that none of the doses that were tested showed meaningful clinical benefit over placebo.Cara Therapeutics president and CEO Christopher Posner said the following ...